
CRBP Stock Forecast & Price Target
CRBP Analyst Ratings
Bulls say
Corbus Pharmaceuticals is expected to continue its positive momentum with promising data from their pipeline, including the ongoing CANYON-1 trial and the upcoming TEMPO-1 trial evaluating CRB-701 in second-line oropharyngeal squamous cell carcinoma and CRB-913 in obesity. Additionally, the company remains financially stable with $117.9M in cash, cash equivalents, and investments as of June 30, 2026 to fund current operations and planned expenditures into 2028. However, there are risks associated with any clinical trials, potential competition from other companies, and the need for additional funding that may impact the company's future success.
Bears say
Corbus Pharmaceuticals is facing significant challenges with its development pipeline, as its ADC CRB-701 needs to show more significant results in larger trials and its drug CRB-913 needs to demonstrate an acceptable therapeutic window. Additionally, the company's focus on oncology and obesity may limit its potential market, as it competes with more established and effective treatments in these fields. The company's financials are also concerning, as it has yet to generate significant revenue and investors may lose patience if clinical trials do not produce successful results.
This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares